Christopher Cotton, MD
General Practice · Denver City, TXNPI 1841271681
Payments from drug & device makers
Across 20 payments — averaging $58.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$726
- Astellas Pharma US Inc$174
- Lilly USA, LLC$57
- AbbVie$53
- Pfizer$46
- Novo Nordisk$33
- plus $74 from 4 others
What the payments were for
- Travel & lodging$72662%
- Food & beverage$28224%
- Education$15613%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 2 | $726 |
| Astellas Pharma US Inc | 3 | $174 |
| Lilly USA, LLC | 4 | $57 |
| AbbVie | 2 | $53 |
| Pfizer | 3 | $46 |
| Novo Nordisk | 2 | $33 |
| Sanofi Pasteur Inc. | 1 | $25 |
| Mylan Specialty L.p. | 1 | $21 |
| Aytu Biopharma, Inc. | 1 | $16 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MAKO$726
How this compares
$1,164 in reported general payments places this provider in the 85th percentile of 8,074 general practice providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 172 | $138,732 |
| EliquisApixaban | 180 | $119,792 |
| FarxigaDapagliflozin Propanediol | 121 | $83,544 |
| MounjaroTirzepatide | 49 | $59,152 |
| TrulicityDulaglutide | 60 | $56,865 |
| GlyxambiEmpagliflozin/Linagliptin | 47 | $53,644 |
| OzempicSemaglutide | 45 | $44,935 |
| JanuviaSitagliptin Phosphate | 60 | $40,348 |
| TradjentaLinagliptin | 53 | $36,886 |
| Tresiba Flextouch U-100Insulin Degludec | 37 | $26,404 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 44 | $24,997 |
| RybelsusSemaglutide | 22 | $21,953 |
| JanumetSitagliptin Phos/Metformin Hcl | 32 | $21,817 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 430 | $15,422 |
| Spiriva HandihalerTiotropium Bromide | 15 | $14,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $46 | $119,792180 claims |
| Lilly USA, LLCMounjaro, Trulicity | $57 | $116,018109 claims |
| Novo NordiskOzempic, Rybelsus | $33 | $66,88867 claims |
| Astellas Pharma US IncMyrbetriq | $174 | $7,08515 claims |
| AbbVieLinzess | $53 | $6,87111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,074 general practice providers in Texas.
Other general practice in Denver City
- Olusoji AfuwapeDallas$12.3M
- Karen CummingsPlano$8.4M
- Helen ShpatsHouston$3.3M
- Kelechi AzuoguHouston$2.5M
- Marcus LastimadoFort Bliss$2.3M
- Christina DeanFrisco$1.9M
- Paul ShrodeMissouri City$1.2M
- Sheila SchmidtPearland$811K
- Danielle CoulterSan Antonio$681K
- Alan DouglasSan Antonio$609K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.